<PubmedArticle><MedlineCitation Status="PubMed-not-MEDLINE" Owner="NLM"><PMID Version="1">39323840</PMID><DateRevised><Year>2024</Year><Month>09</Month><Day>27</Day></DateRevised><Article PubModel="Electronic-eCollection"><Journal><ISSN IssnType="Print">2405-8440</ISSN><JournalIssue CitedMedium="Print"><Volume>10</Volume><Issue>18</Issue><PubDate><Year>2024</Year><Month>Sep</Month><Day>30</Day></PubDate></JournalIssue><Title>Heliyon</Title><ISOAbbreviation>Heliyon</ISOAbbreviation></Journal><ArticleTitle>A real-world study of BBIBP-CorV vaccine effectiveness in a Sri Lanka rural province.</ArticleTitle><Pagination><StartPage>e37662</StartPage><MedlinePgn>e37662</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">e37662</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.heliyon.2024.e37662</ELocationID><Abstract><AbstractText Label="OBJECTIVE" NlmCategory="UNASSIGNED">Real-world studies assessing the effectiveness of the BBIBP-CorV vaccine in low and middle-income countries are limited. We evaluated the BBIBP-CorV vaccine's effectiveness in reducing COVID-19 symptomatic disease, hospitalisation, severe disease, and mortality during the third wave of the pandemic in Sri Lanka.</AbstractText><AbstractText Label="METHODS" NlmCategory="UNASSIGNED">We conducted a test-negative case-control study in North Central Province from May 2021 to February 2022. Evidence of vaccination was obtained from the national registry. The PCR-positive patients were cases, while negative individuals were controls. Adjusted vaccine effectiveness (aVE) was computed for fully, partially, and non-vaccinated groups in reducing symptomatic disease, hospitalisation, severe disease, and mortality.</AbstractText><AbstractText Label="RESULTS" NlmCategory="UNASSIGNED">Our study involved 3305 cases and 3418 controls. The overall aVE for preventing PCR-positive infection in fully vaccinated was 30·8 % (95 % CI:17·9-41·6). In fully vaccinated over 60 years, the overall aVE was 72·3 % (95 % CI: 49·7-84·8). Full vaccination with BBIBP-CorV is effective in reducing hospitalisation, severe COVID-19 disease, and death, with aVE rates of 70·3 % (95 % CI: 57·9-79·0), 88·9 % (95 % CI: 81·8-93·2), and 92·3 % (95 % CI: 84·8-96·1) respectively.</AbstractText><AbstractText Label="CONCLUSION" NlmCategory="UNASSIGNED">Individuals who have received two doses of the BBIBP-CorV vaccine are protected against hospitalisation, severe COVID-19 disease, and death. Duration of protection against hospitalisation, severe COVID-19, and fatal COVID-19 sustained at least 121 days, with no sign of waning during that time.</AbstractText><CopyrightInformation>© 2024 The Authors.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Wijekoon</LastName><ForeName>Lanka</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Faculty of Medicine &amp; Allied Science, Rajarata University of Sri Lanka, Sri Lanka.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wickramasinghe</LastName><ForeName>Nuwan</ForeName><Initials>N</Initials><AffiliationInfo><Affiliation>Faculty of Medicine &amp; Allied Science, Rajarata University of Sri Lanka, Sri Lanka.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Rathnasekara</LastName><ForeName>Thilina</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>Faculty of Medicine &amp; Allied Science, Rajarata University of Sri Lanka, Sri Lanka.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Somathilake</LastName><ForeName>Thejana</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>Faculty of Medicine &amp; Allied Science, Rajarata University of Sri Lanka, Sri Lanka.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sarathchandra</LastName><ForeName>Chamara</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Faculty of Medicine &amp; Allied Science, Rajarata University of Sri Lanka, Sri Lanka.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Senanayake</LastName><ForeName>Hemal</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>Faculty of Medicine &amp; Allied Science, Rajarata University of Sri Lanka, Sri Lanka.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Weerawansa</LastName><ForeName>Prasanna</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>Faculty of Medicine &amp; Allied Science, Rajarata University of Sri Lanka, Sri Lanka.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ganegama</LastName><ForeName>Ranjan</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Faculty of Medicine &amp; Allied Science, Rajarata University of Sri Lanka, Sri Lanka.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zhang</LastName><ForeName>Yuntao</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Faculty of Medicine &amp; Allied Science, Rajarata University of Sri Lanka, Sri Lanka.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Yang</LastName><ForeName>Yunkai</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Faculty of Medicine &amp; Allied Science, Rajarata University of Sri Lanka, Sri Lanka.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ma</LastName><ForeName>Rui</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Faculty of Medicine &amp; Allied Science, Rajarata University of Sri Lanka, Sri Lanka.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zhang</LastName><ForeName>Yaowen</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Faculty of Medicine &amp; Allied Science, Rajarata University of Sri Lanka, Sri Lanka.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Xie</LastName><ForeName>Deying</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>Faculty of Medicine &amp; Allied Science, Rajarata University of Sri Lanka, Sri Lanka.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Li</LastName><ForeName>Zhaofeng</ForeName><Initials>Z</Initials><AffiliationInfo><Affiliation>Faculty of Medicine &amp; Allied Science, Rajarata University of Sri Lanka, Sri Lanka.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Liu</LastName><ForeName>Xiaodan</ForeName><Initials>X</Initials><AffiliationInfo><Affiliation>Faculty of Medicine &amp; Allied Science, Rajarata University of Sri Lanka, Sri Lanka.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Qin</LastName><ForeName>Shouyi</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Faculty of Medicine &amp; Allied Science, Rajarata University of Sri Lanka, Sri Lanka.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Siribaddana</LastName><ForeName>Sisira</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Faculty of Medicine &amp; Allied Science, Rajarata University of Sri Lanka, Sri Lanka.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2024</Year><Month>09</Month><Day>14</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Heliyon</MedlineTA><NlmUniqueID>101672560</NlmUniqueID><ISSNLinking>2405-8440</ISSNLinking></MedlineJournalInfo><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">BBIBP-CorV</Keyword><Keyword MajorTopicYN="N">COVID-19</Keyword><Keyword MajorTopicYN="N">Effectiveness</Keyword><Keyword MajorTopicYN="N">SARS-CoV-2</Keyword><Keyword MajorTopicYN="N">Sri Lanka</Keyword><Keyword MajorTopicYN="N">Vaccine</Keyword></KeywordList><CoiStatement>The authors declare the following financial interests/personal relationships which may be considered as potential competing interests: No personal renumerations. All authors reports financial support, article publishing charges, and equipment, drugs, or supplies were provided by Beijing Institute of Biological Products Co., Ltd. If there are other authors, they declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2024</Year><Month>5</Month><Day>17</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2024</Year><Month>8</Month><Day>7</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2024</Year><Month>9</Month><Day>7</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2024</Year><Month>9</Month><Day>26</Day><Hour>11</Hour><Minute>43</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2024</Year><Month>9</Month><Day>26</Day><Hour>11</Hour><Minute>42</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2024</Year><Month>9</Month><Day>26</Day><Hour>4</Hour><Minute>21</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2024</Year><Month>9</Month><Day>14</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">39323840</ArticleId><ArticleId IdType="pmc">PMC11422056</ArticleId><ArticleId IdType="doi">10.1016/j.heliyon.2024.e37662</ArticleId><ArticleId IdType="pii">S2405-8440(24)13693-6</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Epidemiology Unit, Ministry of Health  COVID-19, National epidemiological report – Sri Lanka. 2023. https://www.epid.gov.lk/high-endemic-diseases-outbreaks</Citation></Reference><Reference><Citation>Epidemiology Unit, Ministry of Health  COVID-19 epidemiology Sri Lanka. 2023. https://www.epid.gov.lk/storage/post/pdfs/en_649aaae7d47b7_esummary-april_2023.pdf</Citation></Reference><Reference><Citation>Ranasinghe D., Jayathilaka D., Jeewandara C., et al. Molecular epidemiology of AY.28 and AY.104 delta sub-lineages in Sri Lanka. Front. Public Health. 2022;10 doi: 10.3389/fpubh.2022.873633.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fpubh.2022.873633</ArticleId><ArticleId IdType="pmc">PMC9253541</ArticleId><ArticleId IdType="pubmed">35801250</ArticleId></ArticleIdList></Reference><Reference><Citation>Epidemiology Unit, Ministry of Health  Progress of COVID-19 immunization as of 30.10. 2022. https://www.epid.gov.lk/storage/post/pdfs/covid_vaccination_2022-10_30.pdf</Citation></Reference><Reference><Citation>Jeewandara C., Aberathna I., Pushpakumara P., et al. Immune responses to Sinopharm/BBIBP‐CorV in individuals in Sri Lanka. Immunology. 2022;1l7:275–285. doi: 10.1111/imm.13536.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/imm.13536</ArticleId><ArticleId IdType="pubmed">35758860</ArticleId></ArticleIdList></Reference><Reference><Citation>Jeewandara C., Aberathna I., Pushpakumara P., et al. Persistence of immune responses to the Sinopharm/BBIBP-CorV vaccine. Immun Inflamm Dis. 2022;10:e621. doi: 10.1002/IID3.621.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/IID3.621</ArticleId><ArticleId IdType="pmc">PMC9091995</ArticleId><ArticleId IdType="pubmed">35634958</ArticleId></ArticleIdList></Reference><Reference><Citation>Barouch D.H. Covid-19 vaccines — immunity, variants, boosters. N. Engl. J. Med. 2022;387:1011–1020. doi: 10.1056/nejmra2206573.</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/nejmra2206573</ArticleId><ArticleId IdType="pmc">PMC9454645</ArticleId><ArticleId IdType="pubmed">36044620</ArticleId></ArticleIdList></Reference><Reference><Citation>Arambepola C., Wickramasinghe N.D., Jayakody S., et al. Sri Lanka's early success in the containment of COVID-19 through its rapid response: clinical &amp; epidemiological evidence from the initial case series. PLoS One. 2021;16(7) doi: 10.1371/journal.pone.0255394.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0255394</ArticleId><ArticleId IdType="pmc">PMC8321098</ArticleId><ArticleId IdType="pubmed">34324587</ArticleId></ArticleIdList></Reference><Reference><Citation>Amaratunga D., Fernando N., Haigh R., Jayasinghe N. The COVID-19 outbreak in Sri Lanka: a synoptic analysis focusing on trends, impacts, risks, and science-policy interaction processes. Prog. Disaster Sci. 2020;8 doi: 10.1016/j.pdisas.2020.100133.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.pdisas.2020.100133</ArticleId><ArticleId IdType="pmc">PMC7836425</ArticleId><ArticleId IdType="pubmed">34173449</ArticleId></ArticleIdList></Reference><Reference><Citation>Erandi K.K.W.H., Mahasinghe A.C., Perera S.S.N., Jayasinghe S. Effectiveness of the strategies implemented in Sri Lanka for controlling the COVID-19 outbreak. J. Appl. Math. 2020 doi: 10.1155/2020/2954519.</Citation><ArticleIdList><ArticleId IdType="doi">10.1155/2020/2954519</ArticleId></ArticleIdList></Reference><Reference><Citation>World Health Organization  Sri Lanka: WHO coronavirus disease (COVID-19) dashboard with vaccination data. https://covid19.who.int/region/searo/country/lk</Citation></Reference><Reference><Citation>Sumathipala A., Siribaddana S., Patel V. Under-representation of developing countries in the research literature: ethical issues arising from a survey of five leading medical journals. BMC Med. Ethics. 2004;5:5. doi: 10.1186/1472-6939-5-5.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/1472-6939-5-5</ArticleId><ArticleId IdType="pmc">PMC524359</ArticleId><ArticleId IdType="pubmed">15461820</ArticleId></ArticleIdList></Reference><Reference><Citation>World Health Organization  Vaccine efficacy, effectiveness, and protection. 2023. https://www.who.int/news-room/feature-stories/detail/vaccine-efficacy-effectiveness-and-protection</Citation></Reference><Reference><Citation>Evaluation of COVID-19 vaccine effectiveness, interim guidance. https://www.who.int/publications/i/item/WHO-2019-nCoV-vaccine_effectiveness-measurement-2021.1</Citation></Reference><Reference><Citation>The department of census and statistics, Sri Lanka. Mid-Year population estimates by district &amp; sex, 2014 – 2023(contd.) 2023. http://www.statistics.gov.lk/Population/StaticalInformation/VitalStatistics/ByDistrictandSex</Citation></Reference><Reference><Citation>Charlson M.E., Carrozzino D., Guidi J., Patierno C. Charlson comorbidity index: a critical review of clinimetric properties. Psychother. Psychosom. 2022;91:8–35. doi: 10.1159/000521288.</Citation><ArticleIdList><ArticleId IdType="doi">10.1159/000521288</ArticleId><ArticleId IdType="pubmed">34991091</ArticleId></ArticleIdList></Reference><Reference><Citation>World Health Organization  Sri Lanka tracks COVID-19 vaccine jabs and vaccination certificate. https://www.who.int/about/accountability/results/who-results-report-2020-mtr/country-story/2021/sri-lanka</Citation></Reference><Reference><Citation>World Health Organization  International guidelines for certification and classification (coding) of COVID-19 as cause of death. 2023. https://www.who.int/publications/m/item/international-guidelines-for-certification-and-classification-(coding)-of-covid-19-as-cause-of-death</Citation></Reference><Reference><Citation>Premikha M., Chiew C.J., Wei W.E., et al. Comparative effectiveness of mRNA and inactivated whole-virus vaccines against coronavirus disease 2019 (COVID-19) infection and severe disease in Singapore. Clin. Infect. Dis. 2022;75:1442–1445. doi: 10.1093/cid/ciac288.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/cid/ciac288</ArticleId><ArticleId IdType="pmc">PMC9047219</ArticleId><ArticleId IdType="pubmed">35412612</ArticleId></ArticleIdList></Reference><Reference><Citation>Li X.N., Huang Y., Wang W., et al. Effectiveness of inactivated SARS-CoV-2 vaccines against the Delta variant infection in Guangzhou: a test-negative case-control real-world study. Emerg Microbes Infect. 2021;10:1751–1759. doi: 10.1080/22221751.2021.1969291.</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/22221751.2021.1969291</ArticleId><ArticleId IdType="pmc">PMC8425710</ArticleId><ArticleId IdType="pubmed">34396940</ArticleId></ArticleIdList></Reference><Reference><Citation>Ismail AlHosani F., Eduardo Stanciole A., Aden B., et al. Impact of the Sinopharm's BBIBP-CorV vaccine in preventing hospital admissions and death in infected vaccinees: results from a retrospective study in the emirate of Abu Dhabi, United Arab Emirates (UAE) Vaccine. 2022;40:2003–2010. doi: 10.1016/j.vaccine.2022.02.039.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.vaccine.2022.02.039</ArticleId><ArticleId IdType="pmc">PMC8857641</ArticleId><ArticleId IdType="pubmed">35193793</ArticleId></ArticleIdList></Reference><Reference><Citation>Mousa M., Albreiki M., Alshehhi F., et al. Similar effectiveness of the inactivated vaccine BBIBP-CorV (Sinopharm) and the mRNA vaccine BNT162b2 (Pfizer-BioNTech) against COVID-19 related hospitalisations during the Delta outbreak in the UAE. J Travel Med. 2022;29(6):taac036. doi: 10.1093/jtm/taac036.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/jtm/taac036</ArticleId><ArticleId IdType="pmc">PMC8903474</ArticleId><ArticleId IdType="pubmed">35244687</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang Y., Belayachi J., Yang Y., Fu Q., Rodewald L., Li H., et al. Real-world study of the effectiveness of BBIBP-CorV (Sinopharm) COVID-19 vaccine in the Kingdom of Morocco. BMC Publ. Health. 2022;22:1584. doi: 10.1186/s12889-022-14016-9.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12889-022-14016-9</ArticleId><ArticleId IdType="pmc">PMC9392069</ArticleId><ArticleId IdType="pubmed">35987605</ArticleId></ArticleIdList></Reference><Reference><Citation>Belayachi J., Obtel M., Mhayi A., Razine A., Abouqal R. Long term effectiveness of inactivated vaccine BBIBP-CorV (Vero Cells) against COVID-19 associated severe and critical hospitalisation in Morocco. PLoS One. 2022;17(12) doi: 10.1371/journal.pone.0278546.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0278546</ArticleId><ArticleId IdType="pmc">PMC9728886</ArticleId><ArticleId IdType="pubmed">36477077</ArticleId></ArticleIdList></Reference><Reference><Citation>Pilishvili T., Gierke R., Fleming-Dutra K.E., et al. Effectiveness of mRNA covid-19 vaccine among U.S. Health care personnel. N. Engl. J. Med. 2021;385(25):e90. doi: 10.1056/nejmoa2106599.</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/nejmoa2106599</ArticleId><ArticleId IdType="pmc">PMC8482809</ArticleId><ArticleId IdType="pubmed">34551224</ArticleId></ArticleIdList></Reference><Reference><Citation>Fiolet T., Kherabi Y., MacDonald C.J., Ghosn J., Peiffer-Smadja N. Comparing COVID-19 vaccines for their characteristics, efficacy and effectiveness against SARS-CoV-2 and variants of concern: a narrative review. Clin. Microbiol. Infect. 2022;28:202–221. doi: 10.1016/j.cmi.2021.10.005.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cmi.2021.10.005</ArticleId><ArticleId IdType="pmc">PMC8548286</ArticleId><ArticleId IdType="pubmed">34715347</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle>